Medical equipment giant Terumo will recognize a massive loss of approximately $610 million due to the termination of a key supply contract. Consequently, the company has revised its full-year operating profit forecast downward by roughly 38 percent.
Terumo decided to mutually terminate its raw plasma supply cooperation agreement with CSL Plasma, a leading US blood collection company. This move triggers impairment losses on related assets, totaling approximately $610 million (about 97.5 billion yen). Of this amount, impairment losses for US production facilities and manufacturing equipment will account for roughly $450 million (about 72 billion yen), which is a non-cash item. The remaining $160 million (about 25.5 billion yen) represents actual cost burdens such as business losses during the transition period and contract termination fees. Investors should note that these figures may fluctuate based on future negotiations and asset valuations.
This decision stems from a review of future revenue plans for the Terumo BCT related business. Although the cooperation began in 2021, both parties agreed to end the contract after the transition period. Terumo will continue to invest management resources in its core blood and cell technology sectors, focusing on providing solutions for medical institutions and the cell therapy field.
Reflecting this loss impact, Terumo significantly downgraded its full-year consolidated performance forecast for the fiscal year ending March 2027. While sales revenue remains largely flat, operating profit and net income attributable to parent company shareholders are expected to fall by approximately 38 percent. Notably, adjusted operating profit is expected to remain in line with previous years. The impairment loss reduces future depreciation expenses, providing a boost of about 2 billion yen, which offsets approximately 2 billion yen in research and development costs associated with the acquisition of Arsenal Medical.
| Item | Previous Forecast (A) | Revised Forecast (B) | Change | Change Rate | Previous Year (Ref.) |
|---|---|---|---|---|---|
| Sales Revenue | 1,239.0 billion yen | 1,229.5 billion yen | -9.5 billion yen | -0.8% | 1,131.877 billion yen |
| Operating Profit | 257.5 billion yen | 160.0 billion yen | -97.5 billion yen | -37.9% | 176.32 billion yen |
| Net Income | 193.1 billion yen | 120.0 billion yen | -73.1 billion yen | -37.9% | 135.914 billion yen |
The sharp drop in operating profit indicates a reduced revenue contribution from US operations. However, the core business growth remains intact, requiring investors to look past short-term book losses to assess the long-term management foundation.
This contract termination marks Terumo's withdrawal from the "plasma collection device sales" business model in the United States. At the same time, the company is shifting strategy toward higher-value cell therapy sectors, guided by the review of its Terumo BCT related business and the acquisition of Arsenal Medical. The impairment process clears up assets, which also serves to reduce future fixed cost burdens.
Shareholders should view this not merely as a one-time loss, but as evidence of diversifying revenue sources and shifting toward high-margin businesses. While profitability will decline in the short term, this is a structural adjustment necessary for long-term growth. Investors should monitor US medical regulatory trends and progress in new businesses to determine if the stock price is overreacting. The fact that sales remain steady while operating profit drops by more than 30 percent suggests that the balance between cost reduction and product pricing remains intact.
Analyst take
This disclosure signals a fundamental review of Terumo's business model in the US market rather than a temporary loss. As the shift in revenue sources intensifies, while some may worry about short-term P&L impacts (particularly net income), attention should also be paid to potential long-term ROE improvements. Ending the relationship with CSL eliminates plasma management risk domestically, but securing supply chains in other countries becomes a new challenge. The pace of revenue generation in the cell therapy sector, driven by the Arsenal Medical acquisition, will determine whether this decline is offset. Pay close attention to the details of the loss recognition and cash outflow management during the transition period.
